Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint

Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint

Athira Pharma’s stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for its experimental Alzheimer’s drug, fosgonimeton, failed to meet primary and key secondary endpoints. This significant drop reflects investor concern over the future of the company’s approach to treating neurodegenerative diseases, particularly Alzheimer’s. The trial aimed to demonstrate […]

Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study

Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study

Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical Phase 3 clinical trial investigating the efficacy of AMX0035 (sodium phenylbutyrate and taurursodiol) in treating amyotrophic lateral sclerosis (ALS). Despite the anticipation, the study did not meet its primary endpoint […]

Nura Bio kicks off Phase 1 clinical trials for SARM1 inhibitor NB-4746

Nura Bio kicks off Phase 1 clinical trials for SARM1 inhibitor NB-4746

Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase 1 clinical trials for its groundbreaking SARM1 inhibitor, NB-4746. This first-in-class, oral, brain-penetrating inhibitor offers broad therapeutic potential across a range of neurological conditions, including Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Traumatic Brain Injury (TBI), and […]

Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS

Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS

RELYVRIO FDA approval for ALS : Amylyx Pharmaceuticals has secured approval for RELYVRIO (sodium phenylbutyrate and taurursodiol) from the US Food and Drug Administration (FDA) has approved for the treatment of amyotrophic lateral sclerosis (ALS) in adults. RELYVRIO, which is an oral, fixed-dose medication, can be taken either as a monotherapy or with currently approved […]

BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS

BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS

NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the dosing of all the participants in a phase 3 trial of NurOwn (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The late-stage trial enrolled nearly 200 participants, who have been randomized […]

Yumanity secures $500m worth deal with Merck to develop therapies for neurodegenerative disorders

Yumanity secures $500m worth deal with Merck to develop therapies for neurodegenerative disorders

Massachusetts-based Yumanity Therapeutics has secured a drug development deal worth up to nearly $500 million with pharma giant Merck to develop new therapies for neurodegenerative disorders. The partnership is set to combine the drug discovery platform of Yumanity Therapeutics with the development and commercialization expertise in neuroscience of Merck. As per the deal, Merck will […]

Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS

Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS

Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral sclerosis (ALS). The late-stage clinical trial, which will be held globally by the US pharma company for 50 weeks, will feature nearly 350 adults across a broad patient population. The […]

CMD enrolls first patient in placebo-controlled ALS trial of CuATSM

CMD enrolls first patient in placebo-controlled ALS trial of CuATSM

Collaborative Medicinal Development (CMD) has enrolled the first patient in a placebo-controlled clinical trial to evaluate the safety and efficacy of CuATSM in patients with Amyotrophic Lateral Sclerosis (ALS). The Australian biotech company plans to enroll a total of 80 patients across four clinical sites in Australia. Amyotrophic Lateral Sclerosis is also known as Motor […]